StreetInsider.com News Articles

Form 4 Simulations Plus, Inc. For: Jun 01 Filed by: WOLTOSZ WALTER S

Tue, 02 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260602/26591608.html

Form 4 Simulations Plus, Inc. For: Jun 01 Filed by: WOLTOSZ WALTER S

Tue, 02 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260602/26591608.html

Form 144 Simulations Plus, Inc. Filed by: WOLTOSZ WALTER S

Mon, 01 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260601/26584284.html

Form 144 Simulations Plus, Inc. Filed by: WOLTOSZ WALTER S

Mon, 01 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260601/26584284.html

Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference

Thu, 21 May 2026 16:05:00 -0400

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in the 23rd Annual Craig-Hallum Institutional Investor Conference taking place in Minneapolis, Minnesota. Mr. O’Connor will host one-on-one meetings with institutional investors on Thursday, May 28, 2026.

For more information about the events or questions about registration, interested parties should reach out to their contacts at Craig-Hallum.

About Simulations Plus, Inc.

Simulations Plus is a global leader in model-informed and AI-accelerated

Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference

Thu, 21 May 2026 16:05:00 -0400

For more information about the events or questions about registration, interested parties should reach out to their contacts at Craig-Hallum.

About Simulations Plus, Inc.

Simulations Plus is a global leader in model-informed and AI-accelerated

Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference

Thu, 21 May 2026 16:05:00 -0400

For more information about the events or questions about registration, interested parties should reach out to their contacts at Craig-Hallum.

About Simulations Plus, Inc.

Simulations Plus is a global leader in model-informed and AI-accelerated

Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference

Thu, 21 May 2026 16:05:00 -0400

For more information about the events or questions about registration, interested parties should reach out to their contacts at Craig-Hallum.

About Simulations Plus, Inc.

Simulations Plus is a global leader in model-informed and AI-accelerated

Form 4 Simulations Plus, Inc. For: May 11 Filed by: Fiedler-Kelly Jill

Wed, 13 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260513/26485966.html

Form 4 Simulations Plus, Inc. For: May 11 Filed by: Fiedler-Kelly Jill

Wed, 13 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260513/26485966.html

Form 144 Simulations Plus, Inc. Filed by: Fiedler-Kelly Jill

Mon, 11 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260511/26469846.html

Form 144 Simulations Plus, Inc. Filed by: Fiedler-Kelly Jill

Mon, 11 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260511/26469846.html

Simulations Plus partners with NVIDIA for AI drug development workflows

Wed, 06 May 2026 07:55:43 -0400

Simulations Plus Inc. (NASDAQ: SLP) announced a technical collaboration with NVIDIA to develop GPU-accelerated simulation and AI-assisted workflows for drug development modeling applications.

The partnership combines Simulations Plus' scientific engines for physiologically-based pharmacokinetics, pharmacokinetics/pharmacodynamics, and quantitative systems pharmacology with NVIDIA's AI infrastructure. The collaboration aims to accelerate simulation cycles and enable large-scale exploration of model structures and parameters.

NVIDIA will contribute computing infrastructure and expertise in accelerated inference and GPU optimization to improve simulation performance. The company also provides access to its BioNeMo platform and pharmaceutical partner network.

The collaboration focuses on three areas: developing GPU-optimized simulation capabilities, creating AI-assisted scientific workflows, and

Simulations Plus partners with NVIDIA for AI drug development workflows

Wed, 06 May 2026 07:55:43 -0400

Simulations Plus Inc. (NASDAQ: SLP) announced a technical collaboration with NVIDIA to develop GPU-accelerated simulation and AI-assisted workflows for drug development modeling applications.

The collaboration focuses on three areas: developing GPU-optimized simulation capabilities, creating AI-assisted scientific workflows, and

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

Wed, 06 May 2026 07:55:00 -0400

Combines validated scientific engines with accelerated computing and AI to enable more scalable, integrated modeling workflows across the drug development lifecycle

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the launch of a technical collaboration with NVIDIA focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle.

The collaboration brings together Simulations Plus’ validated scientific engines across physiologically-based pharmacokinetics (PBPK), pharmacokinetics/pharmacodynamics (PK/PD), and quantitative systems pharmacology (QSP) with

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

Wed, 06 May 2026 07:55:00 -0400

Combines validated scientific engines with accelerated computing and AI to enable more scalable, integrated modeling workflows across the drug development lifecycle

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the launch of a technical collaboration with NVIDIA focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle.

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

Wed, 06 May 2026 07:55:00 -0400

Combines validated scientific engines with accelerated computing and AI to enable more scalable, integrated modeling workflows across the drug development lifecycle

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the launch of a technical collaboration with NVIDIA focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle.

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

Wed, 06 May 2026 07:55:00 -0400

Combines validated scientific engines with accelerated computing and AI to enable more scalable, integrated modeling workflows across the drug development lifecycle

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the launch of a technical collaboration with NVIDIA focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle.

Form 4 Simulations Plus, Inc. For: May 04 Filed by: WOLTOSZ WALTER S

Tue, 05 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260505/26434737.html

Form 4 Simulations Plus, Inc. For: May 04 Filed by: WOLTOSZ WALTER S

Tue, 05 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260505/26434737.html

Form 4 Simulations Plus, Inc. For: May 04 Filed by: DiBella John Anthony II

Tue, 05 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260505/26434750.html

Form 4 Simulations Plus, Inc. For: May 04 Filed by: DiBella John Anthony II

Tue, 05 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260505/26434750.html

Form 144 Simulations Plus, Inc. Filed by: WOLTOSZ WALTER S

Mon, 04 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260504/26426198.html

Form 144 Simulations Plus, Inc. Filed by: WOLTOSZ WALTER S

Mon, 04 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260504/26426198.html

Form 4 Simulations Plus, Inc. For: May 01 Filed by: Evans Sharlene

Fri, 01 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260501/26417617.html